As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Sacituzumab govitecan within its marketing authorisation for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies.
Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available.